WO1996040258A3 - Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure - Google Patents
Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failureInfo
- Publication number
- WO1996040258A3 WO1996040258A3 PCT/US1996/009342 US9609342W WO9640258A3 WO 1996040258 A3 WO1996040258 A3 WO 1996040258A3 US 9609342 W US9609342 W US 9609342W WO 9640258 A3 WO9640258 A3 WO 9640258A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- angiotensin
- receptor antagonist
- spironolactone
- combination therapy
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL12224696A IL122246A (en) | 1995-06-07 | 1996-06-05 | Spironolactone and angiotensin ii antagonist combination for treatment of congestive heart failure |
AU61580/96A AU6158096A (en) | 1995-06-07 | 1996-06-05 | Spironolactone and angiotensin ii antagonist combination the rapy for treatment of congestive heart failure |
IL16087196A IL160871A0 (en) | 1995-06-07 | 1996-06-05 | A combination of spirolactone and angiostensin ii receptor agonist |
DK96919173T DK0831911T3 (en) | 1995-06-07 | 1996-06-05 | Combination therapy to treat congestive heart failure with spironolactone and angiotensin II antagonist |
JP9501683A JPH11509838A (en) | 1995-06-07 | 1996-06-05 | Combination therapy of spironolactone compounds and angiotensin II antagonists for treating congestive heart failure |
DE69620756T DE69620756T2 (en) | 1995-06-07 | 1996-06-05 | COMBINATION THERAPY FOR TREATING CONGESTIVE HEART FAILURE WITH SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST |
EP96919173A EP0831911B1 (en) | 1995-06-07 | 1996-06-05 | Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure |
BR9608505A BR9608505A (en) | 1995-06-07 | 1996-06-05 | Combination therapy of spironolactone and angiotensin ii antagonists for the treatment of congestive heart failure |
AT96919173T ATE216261T1 (en) | 1995-06-07 | 1996-06-05 | COMBINATION THERAPY FOR THE TREATMENT OF CONGESTIVE HEART FAILURE WITH SPIRONOLACTONE AND ANGIOTENSIN II ANTAGONIST |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48608995A | 1995-06-07 | 1995-06-07 | |
US08/486,089 | 1995-06-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996040258A2 WO1996040258A2 (en) | 1996-12-19 |
WO1996040258A3 true WO1996040258A3 (en) | 1997-01-23 |
Family
ID=23930539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/009342 WO1996040258A2 (en) | 1995-06-07 | 1996-06-05 | Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure |
Country Status (16)
Country | Link |
---|---|
US (1) | US20040102423A1 (en) |
EP (1) | EP0831911B1 (en) |
JP (1) | JPH11509838A (en) |
KR (1) | KR19990022723A (en) |
CN (1) | CN1192696A (en) |
AT (1) | ATE216261T1 (en) |
AU (1) | AU6158096A (en) |
BR (1) | BR9608505A (en) |
CA (1) | CA2224222A1 (en) |
CZ (1) | CZ291268B6 (en) |
DE (1) | DE69620756T2 (en) |
DK (1) | DK0831911T3 (en) |
ES (1) | ES2175098T3 (en) |
IL (1) | IL122246A (en) |
PT (1) | PT831911E (en) |
WO (1) | WO1996040258A2 (en) |
Families Citing this family (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6306826B1 (en) | 1997-06-04 | 2001-10-23 | The Regents Of The University Of California | Treatment of heart failure with growth hormone |
US6211217B1 (en) | 1999-03-16 | 2001-04-03 | Novartis Ag | Method for reducing pericardial fibrosis and adhesion formation |
AU3408801A (en) * | 2000-02-18 | 2001-08-27 | Takeda Chemical Industries Ltd | Tnf-alpha inhibitors |
CA2469435A1 (en) | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
DE10335027A1 (en) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Use of telmisartan and simvastatin for treatment or prophylaxis of cardiovascular, cardiopulmonary and renal diseases e.g. hypertension combined with hyperlipidemia or atherosclerosis |
EP1608319A4 (en) | 2003-04-03 | 2007-02-28 | Univ California | Improved inhibitors for the soluble epoxide hydrolase |
EP1765311A4 (en) | 2004-03-16 | 2009-04-29 | Univ California | Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids |
AU2005295167B2 (en) * | 2004-10-20 | 2012-05-10 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
JP2008520744A (en) * | 2004-11-19 | 2008-06-19 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | Anti-inflammatory pyrazolopyrimidine |
NZ571182A (en) | 2006-04-04 | 2010-09-30 | Univ California | Pyrazolo[3,4-d]pyrimidines |
EP2051696A2 (en) * | 2006-08-18 | 2009-04-29 | Morton Grove Pharmaceuticals, Inc. | Stable liquid levetiracetam compositions and methods |
US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
NZ587051A (en) | 2008-01-04 | 2012-12-21 | Intellikine Llc | Isoquinolinone derivatives, compositions and methods of inhibiting phosphatidyl inositol-3 kinase (pi3 kinase) |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US8637542B2 (en) * | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
US20110224223A1 (en) * | 2008-07-08 | 2011-09-15 | The Regents Of The University Of California, A California Corporation | MTOR Modulators and Uses Thereof |
BRPI0915231A2 (en) | 2008-07-08 | 2018-06-12 | Intellikine Inc | kinase inhibitor compounds and methods of use |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
ES2570429T3 (en) | 2008-10-16 | 2016-05-18 | Univ California | Condensed Ring Heteroaryl Kinase Inhibitors |
US8476282B2 (en) * | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
ES2433225T3 (en) | 2009-01-30 | 2013-12-10 | Takeda Pharmaceutical Company Limited | Compound with condensed rings and use thereof |
CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
WO2011047384A2 (en) | 2009-10-16 | 2011-04-21 | The Regents Of The University Of California | Methods of inhibiting ire1 |
ES2593256T3 (en) | 2010-05-21 | 2016-12-07 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulations |
WO2012064973A2 (en) | 2010-11-10 | 2012-05-18 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CN103648499B (en) | 2011-01-10 | 2017-02-15 | 无限药品股份有限公司 | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
CA2821985C (en) | 2011-01-11 | 2019-07-09 | Dimerix Bioscience Pty Ltd | Combination therapy |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
CN102816126A (en) * | 2011-06-07 | 2012-12-12 | 中国药科大学 | Sulfamoyl-aryl-substituted triazole derivatives with cardiovascular activity, preparation method thereof, and application thereof |
CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2013032591A1 (en) | 2011-08-29 | 2013-03-07 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
CA2846496C (en) | 2011-09-02 | 2020-07-14 | The Regents Of The University Of California | Substituted pyrazolo[3,4-d]pyrimidines and uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
JP2015532287A (en) | 2012-09-26 | 2015-11-09 | ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア | IRE1 regulation |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
CA2925944C (en) | 2013-10-04 | 2023-01-10 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
EP4066834A1 (en) | 2014-03-19 | 2022-10-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2016141182A1 (en) | 2015-03-03 | 2016-09-09 | Yee Richard W | Compositions and methods for treating ocular diseases |
CN108349985A (en) | 2015-09-14 | 2018-07-31 | 无限药品股份有限公司 | Solid form, preparation method, the composition and its application method comprising it of isoquinolines |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2017223422A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
CN109715615A (en) | 2016-06-29 | 2019-05-03 | 蒙特利尔大学 | Biaryl methyl heterocycles |
WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991012001A1 (en) * | 1990-02-13 | 1991-08-22 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted benzyl element |
US5049565A (en) * | 1990-12-07 | 1991-09-17 | Merck & Co., Inc. | Microbial transformation process for preparing anti-hypertensive products |
WO1991015206A1 (en) * | 1990-04-05 | 1991-10-17 | E.I. Du Pont De Nemours And Company | Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists |
EP0481448A1 (en) * | 1990-10-16 | 1992-04-22 | E.R. SQUIBB & SONS, INC. | Dihydropyrimidine derivatives |
US5264447A (en) * | 1992-09-01 | 1993-11-23 | Merck & Co., Inc. | Angiotensin II antagonist |
WO1994009778A1 (en) * | 1992-10-26 | 1994-05-11 | Merck & Co., Inc. | Combinations of angiotensin-ii receptor antagonists and diuretics |
EP0628313A1 (en) * | 1993-06-07 | 1994-12-14 | Takeda Chemical Industries, Ltd. | Combination of benzimidazoles having angiotensin-II antagonistic activity with dinretics or calcium antagonists |
WO1995015166A1 (en) * | 1993-12-02 | 1995-06-08 | Curators Of The University Of Missouri | Use of aldosterone antagonists to inhibit myocardial fibrosis |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3257390A (en) * | 1963-06-12 | 1966-06-21 | Merck & Co Inc | Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents |
DE2652761C2 (en) * | 1976-11-16 | 1985-11-21 | Schering AG, 1000 Berlin und 4709 Bergkamen | 15,16-methylene-spirolactones, processes for their preparation and pharmaceuticals containing them |
DE3506100A1 (en) * | 1985-02-18 | 1986-08-21 | Schering AG, 1000 Berlin und 4709 Bergkamen | 1 (ALPHA) .7 (ALPHA) -DITHIO-SUBSTITUTED SPIROLACTONE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT |
WO1992020662A1 (en) * | 1991-05-10 | 1992-11-26 | Merck & Co., Inc. | Acidic aralkyl triazole derivatives active as angiotensin ii antagonists |
-
1996
- 1996-06-05 JP JP9501683A patent/JPH11509838A/en not_active Abandoned
- 1996-06-05 WO PCT/US1996/009342 patent/WO1996040258A2/en not_active Application Discontinuation
- 1996-06-05 CN CN96196086A patent/CN1192696A/en active Pending
- 1996-06-05 KR KR1019970709165A patent/KR19990022723A/en not_active Application Discontinuation
- 1996-06-05 DK DK96919173T patent/DK0831911T3/en active
- 1996-06-05 EP EP96919173A patent/EP0831911B1/en not_active Expired - Lifetime
- 1996-06-05 BR BR9608505A patent/BR9608505A/en not_active Application Discontinuation
- 1996-06-05 DE DE69620756T patent/DE69620756T2/en not_active Expired - Fee Related
- 1996-06-05 PT PT96919173T patent/PT831911E/en unknown
- 1996-06-05 ES ES96919173T patent/ES2175098T3/en not_active Expired - Lifetime
- 1996-06-05 AU AU61580/96A patent/AU6158096A/en not_active Abandoned
- 1996-06-05 CZ CZ19973848A patent/CZ291268B6/en not_active IP Right Cessation
- 1996-06-05 IL IL12224696A patent/IL122246A/en not_active IP Right Cessation
- 1996-06-05 AT AT96919173T patent/ATE216261T1/en not_active IP Right Cessation
- 1996-06-05 CA CA002224222A patent/CA2224222A1/en not_active Abandoned
-
2002
- 2002-10-15 US US10/271,362 patent/US20040102423A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991012001A1 (en) * | 1990-02-13 | 1991-08-22 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted benzyl element |
WO1991015206A1 (en) * | 1990-04-05 | 1991-10-17 | E.I. Du Pont De Nemours And Company | Treatment of glaucoma and ocular hypertension with imidazole angiotensin-ii receptor antagonists |
EP0481448A1 (en) * | 1990-10-16 | 1992-04-22 | E.R. SQUIBB & SONS, INC. | Dihydropyrimidine derivatives |
US5049565A (en) * | 1990-12-07 | 1991-09-17 | Merck & Co., Inc. | Microbial transformation process for preparing anti-hypertensive products |
US5264447A (en) * | 1992-09-01 | 1993-11-23 | Merck & Co., Inc. | Angiotensin II antagonist |
WO1994009778A1 (en) * | 1992-10-26 | 1994-05-11 | Merck & Co., Inc. | Combinations of angiotensin-ii receptor antagonists and diuretics |
EP0628313A1 (en) * | 1993-06-07 | 1994-12-14 | Takeda Chemical Industries, Ltd. | Combination of benzimidazoles having angiotensin-II antagonistic activity with dinretics or calcium antagonists |
WO1995015166A1 (en) * | 1993-12-02 | 1995-06-08 | Curators Of The University Of Missouri | Use of aldosterone antagonists to inhibit myocardial fibrosis |
Non-Patent Citations (1)
Title |
---|
G.H. ANDERSON ET AL: "DIURETIC THERAPY AND RESPONSE OF ESSENTIAL HYPERTENSION TO SARALASIN", ANNALS OF INTERNAL MEDICINE, vol. 87, no. 2, 1987, pages 183 - 187, XP000610206 * |
Also Published As
Publication number | Publication date |
---|---|
JPH11509838A (en) | 1999-08-31 |
EP0831911B1 (en) | 2002-04-17 |
BR9608505A (en) | 1999-07-06 |
DE69620756T2 (en) | 2002-11-14 |
DE69620756D1 (en) | 2002-05-23 |
CZ291268B6 (en) | 2003-01-15 |
ATE216261T1 (en) | 2002-05-15 |
CZ384897A3 (en) | 1998-05-13 |
DK0831911T3 (en) | 2002-07-22 |
WO1996040258A2 (en) | 1996-12-19 |
EP0831911A2 (en) | 1998-04-01 |
AU6158096A (en) | 1996-12-30 |
US20040102423A1 (en) | 2004-05-27 |
IL122246A (en) | 2004-06-01 |
CA2224222A1 (en) | 1996-12-19 |
IL122246A0 (en) | 1998-04-05 |
CN1192696A (en) | 1998-09-09 |
KR19990022723A (en) | 1999-03-25 |
PT831911E (en) | 2002-09-30 |
ES2175098T3 (en) | 2002-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996040258A3 (en) | Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure | |
NZ310730A (en) | Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for treatment of congestive heart failure | |
IE902139L (en) | Imidazolyl alkenoic acids | |
AU640417B2 (en) | Substituted 5-((tetrazolyl)alkenyl)imidazoles | |
AU8844491A (en) | Renal-selective biphenylalkyl 1h-substituted-1,2,4-triazole angiotensin ii antagonists for treatment of hypertension | |
IE902140L (en) | Imidazolyl alkenoic acids | |
NZ330889A (en) | Cycloalkyl substituted imidazoles and their use in treating CSB/RK/p38 kinase mediated diseases | |
MY110205A (en) | Imidazolyl-alkenoic acids. | |
EP0437103A3 (en) | Substituted 5-(alkyl)carboxamide imidazoles | |
CA2371012A1 (en) | 4-(1h-pyrrol-1-yl) imidazoles | |
WO2002009760A3 (en) | Epoxy-steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure | |
CA2246753A1 (en) | Non-peptidyl vasopressin v1a antagonists | |
EP0726072A3 (en) | Composition for the treatment of hypertension and congestive heart failure, containing an angiotensin II antagonist and an endopeptidase inhibitor | |
AU641952B2 (en) | Substituted N-(imidazolyl)alkyl alanine derivatives | |
AU8534291A (en) | Renal-selective angiotensin ii antagonists for treatment of hypertension | |
CA2072233A1 (en) | Triazolopyrimidine derivatives which are angiotensin ii receptor antagonists; processes for preparing them and pharmaceutical compositions containing them | |
WO1992020651A3 (en) | N-(heteroaryl)-imidazolyl-alkenoic acids | |
MX9709976A (en) | Spironolactone and angiotensin ii antagonist combination therapy for treatment of congestive heart failure. | |
ES2105939A1 (en) | New pyrazole derivatives as angiotensin ii antagonist | |
CA2182477A1 (en) | Pyridyl Imidazole Derivatives and Processes for the Preparation Thereof | |
MX9709978A (en) | Epoxy-steroidal aldosterone antagonist and angiotensin ii antagonist combination therapy for treatment of congestive heart failure. | |
MY118704A (en) | Process for preparation of eprosartan | |
AU3635793A (en) | Pyrazolopyrimidin derivatives as angiotensin II receptor antagonists | |
AU1582097A (en) | 1-(n'-(arylalkylaminoalkyl)) aminoisoindoles; dopamine receptor subtype specificligands | |
NZ504898A (en) | (e)-3-[1-n-butyl-5-[2-(2-carboxyphenyl)methoxy-4-chlorophenyl]-1h-pyrazol-4-yl]-2-[(5-methoxy-2,3-dihydrobenzofuran-6-yl)methyl]-prop-2-enoic acid monoargininyl salt as an endothelin receptor antagonist |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 96196086.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: PV1997-3848 Country of ref document: CZ |
|
ENP | Entry into the national phase |
Ref document number: 2224222 Country of ref document: CA Ref document number: 2224222 Country of ref document: CA Kind code of ref document: A Ref document number: 1997 501683 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019970709165 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996919173 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996919173 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV1997-3848 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1019970709165 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996919173 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: PV1997-3848 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 160871 Country of ref document: IL |
|
WWR | Wipo information: refused in national office |
Ref document number: 1019970709165 Country of ref document: KR |